RETRACTED: Effects of Omega-3 Polyunsaturated Fatty Acids on Inflammatory Markers in COPD

Matsuyama, Wataru; Mitsuyama, Hideo; Watanabe, Masaki; Oonakahara, Ken-ichi; Higashimoto, Ikkou; Osame, Mitsuhiro; Arimura, Kimiyoshi

doi:10.1378/chest.128.6.3817

Cited by 105 publications

(84 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only one randomised controlled trial was found, titled "Effects of Omega-3 Polyunsaturated Fatty Acids on Inflammatory Markers in COPD" by Matsuyama et al, published in the journal Chest in 2005 [6]. This study purported to supplement the diet of 64 COPD patients with an omega-3 PUFA or an omega-6 PUFA supplement for two years, and reported significant improvements in the omega-3 PUFA group in the 6 min walk test, perceived rate of exertion (Borg score) and arterial oxygen saturation (pulse oximetry (SpO2)).…”

Section: Introductionmentioning

confidence: 99%

“…The study also reported a decrease in sputum cytokines (inflammatory regulators) in the group receiving omega-3 PUFA with no change in the omega-6 PUFA group. The study concluded that "nutritional support with an omega-3 PUFA-rich diet is a safe and practical method for treating COPD" [6]. This paper was retracted by the journal in 2008 [7], following an institutional investigation that found data had been falsified by the lead author.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Persistent Citation of the Only Published Randomised Controlled Trial of Omega-3 Supplementation in Chronic Obstructive Pulmonary Disease Six Years after Its Retraction

et al. 2015

View full text Add to dashboard Cite

Scientific articles are retracted infrequently, yet have the potential to influence the scientific literature for years. The only randomised controlled trial to explore the effects of omega-3 polyunsaturated fatty acids in people with chronic obstructive pulmonary disease was retracted in 2008 due to falsified data. The objective of this research was to determine the frequency and nature of citations of this retracted paper. Web of Science and Google Scholar were used to determine the number of times the retracted article was cited. Citations were classified as either "retraction acknowledged" or "retraction not acknowledged". The search was conducted on 6 August 2013 and updated on 25 March 2014. Results: The search resulted in 76 citations, of which 24 occurred prior to the retraction of the article. Of the 52 OPEN ACCESSPublications 2015, 3 18 citations occurring after the retraction, only two acknowledged the retraction. Of the citations not acknowledging the retraction, 20 referred to specific data and 30 cited the reference in passing. This retracted article continues to be cited by authors, suggesting that information about the retraction was unsuccessfully communicated to the scientific community. Continual citation of retracted literature has the potential to bias a field of research and potentially misinform end-users.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Persistent Citation of the Only Published Randomised Controlled Trial of Omega-3 Supplementation in Chronic Obstructive Pulmonary Disease Six Years after Its Retraction

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Conversely, some studies that measured the effect of supplementation on cytokine production by monocytes [12,13] or local rather than systemic levels of cytokines showed significant effects [48]. This discrepancy between the systemic and cell or tissue-specific levels is intriguing.…”

Section: Discussionmentioning

confidence: 99%

Omega 3 (n−3) fatty acids down-regulate nuclear factor-kappa B (NF-κB) gene and blood cell adhesion molecule expression in patients with homozygous sickle cell disease

Daak

Elderdery

Elbashir

et al. 2015

Blood Cells, Molecules, and Diseases

View full text Add to dashboard Cite

Chronic inflammation and reduced blood levels of omega-3 fatty acids (n−3) are known characteristics of sickle cell disease (SCD).The anti-inflammatory properties of n−3 fatty acids are well recognized. Omega-3 treated (n = 24), hydroxyurea (HU) treated (n = 18), and n−3 untreated (n = 21) homozygous SCD patients (HbSS) and healthy (HbAA) controls (n = 25) matched for age (5-16 years), gender and socioeconomic status were studied. According to age (5-10) or (11-16) years, two or three capsules containing 277.8 mg docosahexaenoic (DHA) and 39.0 mg eicosapentaenoic (EPA) or high oleic acid placebo (41%) were assigned to n − 3 treated and n − 3 untreated groups, respectively. Hydroxyurea treated group was on dosage more than 20 mg/kg/day. The effect of supplementation on systemic and blood cell markers of inflammation was investigated. The n− 3 treated group had higher levels of DHA and EPA (p b 0.001) and lower white blood cell count and monocyte integrin (p b 0.05) compared with the n−3 untreated. No difference was detected between the two groups regarding C-reactive protein, granulocytes integrin and selectin, plasma tumour necrosis factor-α and interleukin-10. The n−3 treated group had lowered nuclear factor-kappa B (NF-κB) gene expression compared to n−3 untreated and HU treated groups (p b 0.05). This study provides evidence that supplementation with n− 3 fatty acids may ameliorate inflammation and blood cell adhesion in patients with SCD.

show abstract

“…0 g EPA + DHA/d. Matsuyama et al (2005) have measured both systemic (serum) and sputum TNFa and IL-8 levels in a 2-year intervention with a supplemental intake of 0 . 6 g EPA + DHA/d.…”

Section: Lung Inflammationmentioning

confidence: 99%

Differential immunomodulation with long-chainn-3 PUFA in health and chronic disease

Sijben¹,

2007

View full text Add to dashboard Cite

The balance of intake of n-6 and n-3 PUFA, and consequently their relative incorporation into immune cells, is important in determining the development and severity of immune and inflammatory responses. Some disorders characterised by exaggerated inflammation and excessive formation of inflammatory markers have become among the most important causes of death and disability in man in modern societies. The recognition that long-chain n-3 PUFA have the potential to inhibit (excessive) inflammatory responses has led to a large number of clinical investigations with these fatty acids in inflammatory conditions as well as in healthy subjects. The present review explores the presence of dose-related effects of long-chain n-3 PUFA supplementation on immune markers and differences between healthy subjects and those with inflammatory conditions, because of the important implications for the transfer of information gained from studies with healthy subjects to patient populations, e.g. for establishing dose levels for specific applications. The effects of long-chain n-3 PUFA supplementation on ex vivo lymphocyte proliferation and cytokine production by lymphocytes and monocytes in healthy subjects have been studied in twenty-seven, twenty-five and forty-six treatment cohorts respectively, at intake levels ranging from 0 . 2 g EPA + DHA/d to 7 . 0 g EPA + DHA/d. Most studies, particularly those with the highest quality study design, have found no effects on these immune markers. Significant effects on lymphocyte proliferation are decreased responses in seven of eight cohorts, particularly in older subjects. The direction of the significant changes in cytokine production by lymphocytes is inconsistent and only found at supplementation levels ‡ 2 . 0 g EPA + DHA/d. Significant changes in inflammatory cytokine production by monocytes are decreases in their production in all instances. Overall, these studies fail to reveal strong dose-response effects of EPA + DHA on the outcomes measured and suggest that healthy subjects are relatively insensitive to immunomodulation with longchain n-3 PUFA, even at intake levels that substantially raise their concentrations in phospholipids of immune cells. In patients with inflammatory conditions cytokine concentrations or production are influenced by EPA + DHA supplementation in a relatively large number of studies. Some of these studies suggest that local effects at the site of inflammation might be more pronounced than systemic effects and disease-related markers are more sensitive to the immunomodulatory effects, indicating that the presence of inflamed tissue or 'sensitised' immune cells in inflammatory disorders might increase sensitivity to the immunomodulatory effects of long-chain n-3 PUFA. In a substantial number of these studies clinical benefits related to the inflammatory state of the condition have been observed in the absence of significant effects on immune markers of inflammation. This finding suggests that conditionspecific clinical end points might be more sensitive markers...

show abstract

RETRACTED: Effects of Omega-3 Polyunsaturated Fatty Acids on Inflammatory Markers in COPD

Cited by 105 publications

References 60 publications

Persistent Citation of the Only Published Randomised Controlled Trial of Omega-3 Supplementation in Chronic Obstructive Pulmonary Disease Six Years after Its Retraction

Persistent Citation of the Only Published Randomised Controlled Trial of Omega-3 Supplementation in Chronic Obstructive Pulmonary Disease Six Years after Its Retraction

Omega 3 (n−3) fatty acids down-regulate nuclear factor-kappa B (NF-κB) gene and blood cell adhesion molecule expression in patients with homozygous sickle cell disease

Differential immunomodulation with long-chainn-3 PUFA in health and chronic disease

Contact Info

Product

Resources

About